Immune monitoring in pancreatic cancer
Recruiting
- Conditions
- pancreatic canceralvleesklierkanker
- Registration Number
- NL-OMON27380
- Lead Sponsor
- Foundation for Liver and Gastrointestinal Research (SLO)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 200
Inclusion Criteria
•Age ≥ 18 years
•Diagnosed with resectable or borderline resectable pancreatic cancer, locally advanced pancreatic cancer or metastasized pancreatic cancer
Exclusion Criteria
•Unable to draw blood for study purposes
•Serious concomitant systemic disorders that would compromise the safety of the patient or his/her ability to complete the study, at the discretion of the investigator.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method •To determine the baseline immune signature in pancreatic cancer patients.
- Secondary Outcome Measures
Name Time Method •To investigate whether the immune profile found in the PB reflects the local immune signature of the pancreatic tumor.<br /><br>•To determine the effect of standard of care treatment (neoadjuvant CRTx, adjuvant chemotherapy or palliative chemotherapy) on the expression of co-inhibitory molecules and their ligands on TIL and PB lymphocytes.<br>